Novo Nordisk’s semaglutide achieved explosive sales in 2023. Ozempic alone generated $13,892 million in sales for the year. But now that Hims & Hers has revealed plans to sell compounded semaglutide to the masses, questions arise about how the Dutch pharma giant will respond. 2023 was a banner year for the firm with its diabetes…

A pair of weight-loss drugs —  semaglutide and tirzapatide — could reshape the way we view and treat obesity, according to a Moody’s report dated May 18. The ratings firm notes that Novo Nordisk could benefit from a first-mover advantage in the obesity market as it now has two novel weight loss drugs on the…

Novo Nordisk (NYSE:NVO) has settled a securities lawsuit in Denmark filed in August 2019 in the district court of Glostrup.  In 2019, Novo Nordisk vowed to fight the allegations contained in the lawsuit, which alleged that the company’s insulin-related profits fell at the same time prices and sales increased from February 2015 and February 2017. The…

Novo Nordisk (NYSE:NVO) announced that one of its contract manufacturers filling syringes for its Wegovy (semaglutide) pens in the U.S. market has temporarily ceased manufacturing following a report of Good Manufacturing Practice (GMP) problems. The company projects it will be unable to meet U.S. demand for the drug in the first half of 2022 and…